中文名 | ONX-0914 (PR-957) |
英文名 | (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide |
别名 | 化合物ONX0914 ONX-0914 (PR-957)抑制剂 |
英文别名 | PR957 PR 957 PR-957 PR957 PR-957 PR 957 ONX0914 ONX-0914 ONX 0914 ONX0914 ONX-0914 PR 957(ONX 0914) ONX-0914 (PR-957) N-[2-(4-Morpholinyl)acetyl]-L-alanyl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-tyrosinamide (S)-3-(4-methoxyphenyl)-N-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propanamide |
CAS | 960374-59-8 |
化学式 | C31H40N4O7 |
分子量 | 580.67 |
熔点 | >70oC (dec.) |
溶解度 | DMSO (微溶) 、甲醇 (微溶) |
存储条件 | Refrigerator |
外观 | 固体 |
颜色 | White to Pale Yellow |
靶点 | LMP7 |
体外研究 | ONX-0914作用于LMP7比作用于下一个最敏感的位点β5或LMP2选择性高20到40倍。ONX-0914在体外和体内抑制LMP7特异性的,MHC-I限制性的抗原,对组成型蛋白酶体具有最低的交叉反应性。ONX-0914选择性抑制LMP7,通过该活化的单核细胞和T细胞产生的干扰素-γ和IL-2,而导致白细胞介素-23(IL-23)的产生受抑制。LMP7受抑制导致90% IL-23的产生受抑制,及50%肿瘤坏死因子-α(TNF-α)和IL-6受抑制。 |
体内研究 | ONX-0914处理风湿性关节炎和狼疮小鼠模型,逆转疾病的征兆,并降低细胞浸润,细胞因子产生,及自身抗体水平在良好的耐受剂量。ONX-0914处理小鼠的最大耐受剂量(MTD)为30 mg/kg体重。ONX-0914为LMP7选择性浓度时,抑制60%IFN-g释放,在更高浓度时,抑制90%。ONX-0914还抑制约50%IL-2产生。 |
参考资料 展开查看 | 1: Eleftheriadis T, Pissas G, Antoniadi G, Liakopoulos V, Stefanidis I. Proteasome or immunoproteasome inhibitors cause apoptosis in human renal tubular epithelial cells under normoxic and hypoxic conditions. Int Urol Nephrol. 2016 Feb 26. [Epub ahead of print] PubMed PMID: 26920131. 2: Mundt S, Basler M, Buerger S, Engler H, Groettrup M. Inhibiting the immunoproteasome exacerbates the pathogenesis of systemic Candida albicans infection in mice. Sci Rep. 2016 Jan 18;6:19434. doi: 10.1038/srep19434. PubMed PMID: 26776888; PubMed Central PMCID: PMC4726078. 3: Walker-Caulfield ME, Guo Y, Johnson RK, McCarthy CB, Fitz-Gibbon PD, Lucchinetti CF, Howe CL. NFκB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG. J Neuroinflammation. 2015 Sep 30;12:185. doi: 10.1186/s12974-015-0403-8. PubMed PMID: 26423139; PubMed Central PMCID: PMC4590277. 4: Howland SW, Ng GX, Chia SK, Rénia L. Investigating proteasome inhibitors as potential adjunct therapies for experimental cerebral malaria. Parasite Immunol. 2015 Nov;37(11):599-604. doi: 10.1111/pim.12277. PubMed PMID: 26366636. 5: Zhang HM, Fu J, Hamilton R, Diaz V, Zhang Y. The mammalian target of rapamycin modulates the immunoproteasome system in the heart. J Mol Cell Cardiol. 2015 Sep;86:158-67. doi: 10.1016/j.yjmcc.2015.07.027. Epub 2015 Aug 1. PubMed PMID: 26239133. 6: Zilberberg J, Matos J, Dziopa E, Dziopa L, Yang Z, Kirk CJ, Assefnia S, Korngold R. Inhibition of the Immunoproteasome Subunit LMP7 with ONX |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.722 ml | 8.611 ml | 17.221 ml |
5 mM | 0.344 ml | 1.722 ml | 3.444 ml |
10 mM | 0.172 ml | 0.861 ml | 1.722 ml |
5 mM | 0.034 ml | 0.172 ml | 0.344 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!